---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-002980"
form_type: "8-K"
ticker: "CLDX"
cik: "0000744218"
company_name: "Celldex Therapeutics, Inc."
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T06:03:29.418450+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Celldex Q1 net loss widens to $53.8M; Phase 3 CSU enrollment ongoing, multiple data readouts in 2025

## Summary
- Net loss of $53.8M ($0.81/share) vs $32.8M ($0.56/share) in Q1 2024; R&D expenses rose to $52.6M.
- Cash, equivalents and marketable securities $673.3M at March 31, sufficient to fund operations through 2027.
- Phase 3 barzolvolimab CSU studies (EMBARQ-CSU1/2) enrolling; Phase 2 EoE enrollment complete; data expected 2025.
- 76-week CSU Phase 2 data accepted for late-breaking oral presentation at EAACI June 2025.
- Bispecific CDX-622 Phase 1 in healthy volunteers enrolling; Part 1 data expected in 2025.

## SEC filing metadata
- accession: 0001171843-25-002980
- form_type: 8-K
- ticker: CLDX
- cik: 0000744218
- company_name: Celldex Therapeutics, Inc.
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/744218/000117184325002980/0001171843-25-002980-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/744218/000117184325002980/f8k_050825.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-002980
- JSON: https://secwatch.observer/filing/0001171843-25-002980.json
- Plain text: https://secwatch.observer/filing/0001171843-25-002980.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.